Ch. XI — Regulatory and legal landscape

Chapter XI of Post-2010 Psychedelics: An Expert-Panel Review. For the executive summary and full table of contents, start there.

Abstract. This chapter inventories the regulatory and legal architecture under which clinical and adult-use psychedelic activity is now conducted across the principal jurisdictions of interest. It focuses on what has actually been put in place — schedules, exemptions, designations, statutes, prescribers, clients, capital — rather than on what has been promised, and treats the 2024 Lykos episode as a regulatory-process narrative (timeline, votes, letters, retractions, corporate response). Methodology critique of underlying trials is the subject of Chapter XII.

11.1 United States federal status

At federal level, all classical serotonergic psychedelics (LSD, psilocybin, psilocyn, DMT, mescaline) and MDMA remain Schedule I controlled substances under the Controlled Substances Act of 1970 (21 U.S.C. § 812).¹ Ibogaine retains the same status; 5-MeO-DMT was placed in Schedule I by DEA final rule effective January 2011. DEA’s posture as of 2026 remains that rescheduling is contingent on positive FDA action and a formal eight-factor analysis; Schedule I research registration continues unchanged, with manufacturing exemptions granted case-by-case for GMP synthetic supply to FDA-authorised trial sponsors.

11.1a DEA eight-factor analysis and the FDA-approval-to-rescheduling timeline

FDA approval of a Schedule I substance does not automatically reschedule it. Under 21 U.S.C. §811, scheduling actions are independent regulatory determinations made by the DEA after HHS/FDA submits a scientific-and-medical evaluation and scheduling recommendation. The Improving Regulatory Transparency in New Medical Therapies Act (codified at 21 U.S.C. §811(j)) gives DEA 90 days to commence the rulemaking process upon receipt of the HHS recommendation for an FDA-approved Schedule I substance, but the rulemaking itself (NPRM, public comment, response, optional administrative-law-judge hearing, final rule) can take 1–3 years to conclude. If a hearing is requested and granted, the final action can be delayed by 2+ years.²

The substantive scheduling review applies the §811(c) eight-factor analysis: (1) actual or relative potential for abuse; (2) scientific evidence of the drug’s pharmacological effect; (3) state of current scientific knowledge regarding the drug; (4) history and current pattern of abuse; (5) scope, duration, and significance of abuse; (6) risk to the public health; (7) psychic or physiological dependence liability; (8) immediate-precursor status. For psilocybin, the eight-factor record will include positive findings under factors (2) and (3) (mature pharmacology, large Phase 3 dataset); contested findings under factors (4) and (5) (the post-2010 retreat-tourism economy and Oregon/Colorado state programmes provide a pattern-of-use record that is materially different from pre-2020 illicit use); a low-but-non-zero finding under (7) (DSM-5 hallucinogen-use disorder criteria apply but classical psychedelics are not classically dependence-producing in the SUD sense). FDA’s HHS scheduling recommendation will be central; DEA may accept, modify, or (rarely) override the recommendation.

The Epidiolex (cannabidiol) precedent illustrates the timeline at its fastest end: FDA approved Epidiolex on 25 June 2018; HHS submitted its eight-factor analysis to DEA; DEA published a final rule placing FDA-approved CBD products in Schedule V on 28 September 2018 — approximately three months from FDA approval. Critically, the DEA scheduled only the FDA-approved product, not cannabidiol as a whole; raw or non-FDA-approved CBD remained Schedule I. A parallel psilocybin action would plausibly create a “FDA-approved-COMP360” Schedule III/IV/V carve-out while leaving non-pharmaceutical psilocybin in Schedule I.³ The Marinol (synthetic THC, dronabinol) precedent shows a longer arc: FDA approved Marinol in 1985; DEA rescheduled it from Schedule I to Schedule II in July 1986; a further petition led to a Schedule II → Schedule III reclassification in July 1999 — fourteen years after initial approval.⁴

Three implementation implications follow. First, in the FDA-approved-but-not-yet-DEA-rescheduled window (plausibly 3–24 months for psilocybin), prescribers, pharmacies, and certified healthcare settings must maintain Schedule I controlled-substance handling protocols — a materially different infrastructure burden than Schedule III/IV/V pharmaceutical distribution. Second, DEA scheduling determinations for state-program psilocybin (Oregon Measure 109 service centres, Colorado healing centres) are independent of any FDA-approved-product scheduling action and may remain unchanged. Third, the report’s framing of “Schedule I-to-prescription pathway” elsewhere should be read as compressed shorthand for two sequential regulatory actions (FDA NDA approval + DEA rescheduling rulemaking) operating on different timelines under different statutory authorities, not a single regulatory event.

The FDA review pathway has, by contrast, been actively used. Breakthrough Therapy designations (BTDs) for psychedelic-assisted indications between 2017 and 2026:

The pattern is informative: three BTDs between 2017 and 2019, then nothing until March 2024, when MindMed and Cybin received designations within six days of each other. The 2024–2026 cluster is concentrated in non-MDMA serotonergic compounds — in part reflecting the regulatory shock of the Lykos episode (§11.2) and in part reflecting Phase 2 data maturation for novel chemical entities. (External sources occasionally date Cybin’s BTD to June 2024; the press release of record is 13 March 2024. GH Research has not announced a BTD for GH001 as of the freeze date.)

11.2 The Lykos episode: regulatory timeline

The Lykos / midomafetamine NDA is the highest-stakes regulatory event in the modern history of the field, and its mechanics warrant a step-by-step accounting. This section restricts itself to the regulatory-process record; methodological forensics — functional unblinding, expectancy, the British Columbia therapist case, suicidality reporting, the structural relationship between MAPS PBC and the trial sponsor — are deferred to Chapter XII.

Timeline.

• August 2017: FDA grants Breakthrough Therapy designation to MAPS’ MDMA-assisted psychotherapy for PTSD.⁵
• 2018–2021: Phase 3 trial MAPP1 conducted; Mitchell et al. Nat. Med. June 2021 reports primary endpoint met (PMID 33972795).¹²
• 2022–2023: Confirmatory Phase 3 MAPP2 conducted; Mitchell et al. Nat. Med. October 2023 reports primary endpoint met (PMID 37709999).¹³
• 23 January 2024: MAPS Public Benefit Corporation rebranded as Lykos Therapeutics; CEO transitions and outside investment (PBC structure retained).
• February 2024: Lykos submits NDA 215455.
• 26 March 2024: ICER releases Draft Evidence Report on midomafetamine-AT for PTSD.¹⁴
• 4 June 2024: Psychopharmacologic Drugs Advisory Committee meets. Vote on “effective in treating patients with PTSD”: 2 yes, 9 no, 0 abstain. Vote on “benefits outweigh the risks”: 1 yes, 10 no, 0 abstain.¹⁵
• 27 June 2024: ICER releases Final Evidence Report; New England CEPAC votes 14–1 (vs no MDMA-AT) and 15–0 (vs short-term trauma-focused psychotherapy) that current evidence is inadequate to demonstrate net health benefit; ICER declines to compute a health-benefit price benchmark.¹⁶
• 9 August 2024: FDA issues Complete Response Letter denying the application and requesting an additional adequately controlled Phase 3 trial.¹⁷
• 10 August 2024: Psychopharmacology (Springer) retracts three Lykos/MAPS-affiliated papers (two pooled Phase 2 analyses and one paper on antidepressant taper effects) for protocol violations amounting to unethical conduct at a Canadian study site and undisclosed competing interests.¹⁸
• 15 August 2024: Lykos announces reorganisation, including a workforce reduction of approximately 75% and departures of senior officers.¹⁹
• September 2025: FDA publicly releases the Complete Response Letter (initially issued in confidence in August 2024) under transparency-initiative reforms, allowing external analysis of the specific deficiencies cited.²⁰

The CRL describes deficiencies in three families: (i) functional unblinding and expectancy effects; (ii) safety-reporting infrastructure including suicidality and abuse-potential characterisation; and (iii) the structural conflation of pharmacotherapy with a non-manualised psychological intervention of contested provenance. The substance of these is reviewed in Chapter XII; the regulatory point here is that the FDA’s negative determination was supported by an unusually concordant AdCom vote, an independent value-assessment body, and a peer-reviewed-journal retraction process within a ten-week window.

11.2a CRL specifics from the September 2025 public release

On 4 September 2025, FDA published 89 previously-confidential Complete Response Letters under its transparency initiative; the Lykos NDA 215455 CRL was among them.²⁰²¹ The publicly-released text gives a granularity the pre-disclosure summary lacks. Three families of cited deficiency, with the specific findings:

Efficacy and durability deficiencies. FDA flagged the MPLONG long-term follow-up study (intended to support durability claims) as inadequate for multiple structural reasons: a single follow-up visit rather than longitudinal trajectory data; variable timing between original dosing and follow-up assessment (6 months to 2 years across participants); low enrolment with potential self-selection bias toward responders; and post-trial receipt of confounding therapies (other psychotherapies, medication) that the design could not control. The CRL concluded the durability dataset does not establish whether MDMA-AT’s clinical benefit persists, whether retreatment is needed, or what the long-term management protocol should be. The Phase 3 MAPP1/MAPP2 efficacy data were not separately invalidated, but the long-term-effect claim — load-bearing for the registrational case — was not supported.

Safety reporting infrastructure deficiencies. The CRL specifically cited (i) protocol-level instructions to trial sites not to record certain euphoria-like effects as adverse events — a finding with direct implications for the abuse-potential characterisation FDA requires for any Schedule I-or-II drug seeking labelled use; (ii) general reliability concerns about safety reporting at multiple sites; (iii) inadequate characterisation of cardiovascular adverse events given MDMA’s known sympathomimetic profile. The CRL lists eight specific safety-data components requiring further work.

Selection-bias and functional-unblinding deficiencies. Approximately 40% of MAPP1/MAPP2 participants reported prior MDMA use — a recruitment pattern that, combined with the dramatic acute experience of an unblinded active dose, raises functional-unblinding and expectancy concerns FDA characterised as “not adequately addressed” by the submitted analyses. The CRL framed this as a design-level constraint requiring a substantially different next-trial protocol, not a post-hoc statistical correction.

Requested remediation. The CRL specified nine trial-design recommendations for an additional adequately controlled Phase 3 trial, including (publicly known): pre-registered blinding diagnostics with arm-by-arm correct-guess data; standardised AE-reporting protocols with central monitoring of euphoria-like effects; a comparator and study population that materially reduces the self-selection-from-prior-use confound; and pre-specified durability assessment with multi-visit longitudinal design. The MAPS public response and Lykos’s subsequent Phase 3 protocol communications acknowledge these requirements broadly; specific Type C meeting outcomes between FDA and Lykos on the redesigned protocol are not in the public record as of the freeze date.²²

This is the FDA-cited level of detail. The methodological and ethics-of-conduct dimensions of these deficiencies — and the parallel ICER assessment — are reviewed in Ch XII §12.8 and §12.9. The regulatory implication for the broader field is that FDA has now publicly articulated the standard against which subsequent psychedelic NDAs (Compass COMP005/006 expected Q4 2026; downstream MM120, BPL-003, GH001 programmes) will be measured: blinding diagnostics, AE-reporting integrity, durability data integrity, and selection-pattern characterisation are all panel-load-bearing in a way they may not have been pre-Lykos.

11.2b FDC §505(d) “substantial evidence of effectiveness” and the COMP005/006 question

The statutory bar for FDA approval is “substantial evidence of effectiveness” under 21 U.S.C. §355(d). The canonical 1962 amendments interpretation required two adequate and well-controlled investigations providing independent evidence of efficacy.²³ The 1997 FDA Modernization Act (FDAMA §115) amended §355(d) to permit FDA to consider “data from one adequate and well-controlled clinical investigation and confirmatory evidence” if FDA determines such data are sufficient; FDA’s 1998 Guidance “Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products” operationalises both pathways.²⁴ The 2019 and 2023 supplemental guidances refine the confirmatory-evidence framework further but do not alter the underlying standard.²⁵

Two questions about the Compass COMP005/006 package are panel-load-bearing under this framework. First, do COMP005 and COMP006 constitute two independent adequate-and-well-controlled investigations? The 1998 Guidance is explicit that “independent confirmatory replication” requires meaningful design diversity — different sponsor, different population, different design choices that make the second trial a genuine retest rather than a sample-size doubling. COMP005 and COMP006 share sponsor (Compass), protocol family (single 25 mg COMP360 dose with psychological support frame), primary endpoint (MADRS change), comparator architecture (placebo or 1 mg active control), site network, and rater protocol. The trials differ on sample size (258 vs 581), comparator choice (inert placebo vs 1 mg active), and primary-endpoint window (Week 6 in both, but COMP006 includes a 10 mg arm). The argument for “two independent investigations” rests on COMP006’s three-arm dose-response design providing internal-consistency verification of COMP005’s two-arm result; the argument against is that the trials share so much architecture that the second is closer to a confirmatory/extension than to an independent replication. Second, if the package is read as “one adequate-and-well-controlled trial plus confirmatory evidence” rather than “two adequate-and-well-controlled investigations,” what counts as the confirmatory evidence? The 1998/2023 guidance enumerates: trials of the same drug in related indications (Compass has Phase 2 MDD and Phase 2b/3 TRD data — partial overlap); mechanism-of-action evidence (the intracellular-5-HT2A neuroplasticity thesis, Ch III–IV); pharmacokinetic/pharmacodynamic bridging; natural-history data; and meta-analytic synthesis with prior psilocybin trials. The 2023 draft guidance is explicit that confirmatory evidence must be of a type and quality that, combined with the single trial, provides the same degree of certainty as two independent trials would.

Which framework Compass is pursuing is not publicly clear. The pre-NDA Type B and Type C meeting record with FDA’s Division of Psychiatry is confidential; Compass’s investor communications speak generically of “two positive Phase 3 trials” without engaging the independence question explicitly. The panel-relevant takeaway is that FDA’s reviewer will work this question explicitly in the medical-officer review, and the report should not assume the §505(d) bar is met by virtue of two positive readouts — the statutory reasoning will need to be argued, and the design-parallelism between COMP005 and COMP006 is a vulnerability that the September 2025 Lykos CRL release suggests FDA reviewers are now more willing to articulate publicly.

11.2c REMS architecture for psilocybin-assisted therapy

The Spravato (esketamine) Risk Evaluation and Mitigation Strategy with Elements to Assure Safe Use (REMS-ETASU) is the load-bearing regulatory precedent for any psilocybin approval. FDA’s Spravato REMS has four ETASU components: B (pharmacy certification), C (healthcare setting certification), E (patient monitoring), and F (patient enrolment registry).²⁶ A parallel psilocybin REMS would plausibly require each, with parameters scaled to psilocybin’s pharmacology:

• In-clinic administration with no take-home dispensing. Spravato’s certified pharmacy/setting structure prohibits direct-to-patient dispensing; the drug is held at the certified Healthcare Setting and administered there. Psilocybin REMS would almost certainly carry the same constraint, with the same downstream implications for retail-pharmacy distribution and prior-authorisation processes.
• Minimum post-dose observation. Spravato requires a 2-hour minimum post-administration monitoring period under direct healthcare-provider observation, with documented vital-sign assessment, dissociation/sedation resolution, and discharge readiness. Psilocybin’s pharmacokinetic envelope (T_max ~1.5–2 h; total subjective duration 4–6 h) would push the observation requirement to 6–8 hours — three to four times Spravato’s window, with corresponding implications for facility throughput and per-session staffing cost. This is the single largest operational divergence from the Spravato precedent.
• Certified prescriber and facilitator training. Spravato requires prescriber certification through the SPRAVATO REMS programme; psilocybin would require both prescriber certification and facilitator-level certification (since psychological-support staff are present during dosing and observation, a feature absent from the Spravato administration model). The Compass investor materials reference a 10–12-hour structured-support training curriculum; a registrational-grade REMS would plausibly require a multi-day in-person practical component plus supervised case-experience hours, more in the Oregon-Measure-109 (120-hour didactic + 40-hour practicum) range than the Spravato (online + brief practical) range. Whether this would be a REMS requirement or a separate professional-credentialing layer is itself a policy choice.
• Certified Healthcare Setting category. Spravato’s “Outpatient Healthcare Setting” certification requires facility-level enrolment, training documentation, AE-reporting infrastructure, and emergency-response capability for sedation/dissociation events. Psilocybin would require analogous facility certification, with the additional requirement of a dedicated dosing room (no general-purpose clinical space) for 6–8 hour sessions — meaning the per-site capital investment to establish a certified psilocybin setting is materially higher than for Spravato. Industry-analyst estimates put facility set-up cost in the $50,000–$200,000 range per site (vs Spravato’s $10,000–$30,000), depending on existing infrastructure.
• Patient enrolment registry. Spravato requires patient enrolment in the REMS-managed registry, with AE reporting flowing back through the certified setting. Psilocybin would parallel this; the registry data would also feed the post-marketing-surveillance commitments (§11.2d).

The aggregate per-session cost under a Spravato-analog REMS structure is the panel-relevant economic anchor. Spravato real-world data places the insurance-reimbursed cost per session at approximately $1,400–$2,000 (clinic-billed Buy-and-Bill model), with out-of-pocket patient cost averaging $250 per session (with insurance) or $590–$885 per session (uninsured).²⁷ Per-session cost for a Spravato-analog psilocybin REMS would plausibly run $1,500–$2,500 per session, driven primarily by (i) the longer observation window (3–4× Spravato’s staffing-hours), (ii) the addition of a facilitator-grade staff member during dosing, and (iii) higher per-site fixed costs amortised across lower session-throughput. Under a labelled-therapy-component approval (i.e., FDA labels the structured psychological support as part of the approved indication), the per-course cost (preparation sessions + dosing + integration) could reach $3,500–$6,500 per patient — comparable to the Oregon-services-economy pricing (§11.3) but with insurance reimbursement attached.

A specific access-equity implication follows. Spravato’s REMS, even with insurance reimbursement, has produced uneven geographic access — concentration in metropolitan areas with sufficient certified-setting density and patient volume to sustain throughput; sparse coverage in rural and lower-income areas. The Spravato deployment trajectory (FDA approval March 2019; ~5,500 certified treatment centers and ~150,000 patients treated through 2024 per Janssen/Otsuka aggregate disclosure) gives the order-of-magnitude reference for psilocybin deployment under analogous REMS. Number of certified psilocybin sites achievable in the first 24 months post-approval is plausibly in the low thousands at most; geographic coverage will be metropolitan-skewed; payer-coverage status will be the principal determinant of patient throughput. The cost-effectiveness argument the field has emphasised (single-dose paradigm; durable response; potential cost-equivalence with chronic conventional antidepressant treatment) is conditional on this REMS-and-access infrastructure operating at scale — which it has not yet been demonstrated to do for any psychedelic.

11.2d Post-marketing commitments (PMRs / PMCs), PREA, and pregnancy labelling

Approval of a novel psychiatric agent for a Schedule I substance with a structured-therapy component will almost certainly come with a substantial post-marketing-commitment package. The Spravato precedent and standard FDA practice for psychiatric NDAs in the past decade suggest the predictable Compass PMR/PMC package includes:

• Phase 4 active-comparator effectiveness study. Comparative-effectiveness study against esketamine, against augmentation strategies (atypical antipsychotic, lithium), and/or against electroconvulsive therapy in TRD. The Phase 3 evidence base is placebo-or-low-dose-comparator only; FDA will plausibly require a head-to-head against an established TRD treatment for post-approval label expansion or formulary positioning.
• Long-term durability registry. A prospective post-approval registry with multi-year follow-up to address the Ch V §5.8 durability-beyond-six-months question that the Phase 3 trials do not resolve. This parallels the MPLONG-style design but with FDA-mandated structural requirements (longitudinal visits; central data adjudication; standardised co-medication tracking).
• REMS modification post-approval based on real-world data. Spravato’s REMS has been modified post-approval (notably the at-home administration option added in 2023 for selected patients); a psilocybin REMS would be expected to evolve similarly, with the post-approval registry data providing the empirical basis.
• Abuse-potential post-marketing surveillance. Schedule I substances reaching the prescription market are subject to enhanced abuse-potential post-marketing surveillance under FDA’s 2010 Abuse-Potential Assessment guidance, with structured reporting on diversion, off-label use, and emerging abuse patterns. Psilocybin’s profile here is notably different from MDMA’s (lower dependence liability; documented self-limiting acute experience; existing illicit market is small-volume relative to MDMA/cocaine/opioids) but the surveillance commitment will exist regardless.
• Pediatric assessment under PREA. The Pediatric Research Equity Act (21 U.S.C. §355c) requires sponsors of NDAs covering adult conditions to submit an initial Pediatric Study Plan (iPSP) within 60 days of the end-of-Phase-2 meeting, with subsequent pediatric assessment unless FDA grants a waiver (for indications where pediatric studies are “impossible or highly impracticable” or where evidence “strongly suggests” pediatric inappropriateness) or a deferral (more time needed).²⁸ Psilocybin’s PSP status is publicly unknown; deferral is the expected outcome given (i) the safety-population concerns about developing brains, (ii) the absence of pediatric efficacy hypothesis-generating data, and (iii) the precedent of Spravato’s pediatric assessment having been deferred. Eventually, FDA will require some pediatric data; the deferral horizon is plausibly 5–10 years post-approval, with adolescent (12–17) TRD the likely first pediatric indication explored.
• Pregnancy and Lactation labelling under PLLR. The 2014 Pregnancy and Lactation Labeling Rule (PLLR) replaced the old A/B/C/D/X pregnancy categories with narrative subsections covering Pregnancy, Lactation, and Females and Males of Reproductive Potential.²⁹ Psilocybin’s labelling under PLLR will require (i) animal-reproduction data summary (the public literature is sparse; the Compass NDA package will include modern GLP-compliant studies); (ii) human pregnancy registry plans (no such registry exists for psilocybin as of the freeze date; Compass would plausibly commit to one as a PMR); (iii) lactation-transfer characterisation (likely modeled from PK parameters rather than human breast-milk data); (iv) contraception requirements for the indication (likely worded as a precaution for women of reproductive potential, with timing requirements tied to the multi-day post-session window). Pregnancy exclusion from Phase 3 trials means the labelling will be data-thin at approval and is a likely future-PMR area.

11.3 Oregon Measure 109 (Psilocybin Services Act)

Oregon Measure 109 passed in November 2020 with 55.8% in favour as the first U.S. statute creating a regulated adult-use psilocybin services framework.³⁰ The Oregon Psilocybin Services (OPS) section of the Oregon Health Authority began accepting licence applications on 2 January 2023; first service centres opened in summer 2023. Crucially, the framework is services, not medical: psilocybin is administered in supervised sessions at licensed Service Centers by licensed Facilitators; no diagnosis is required and no insurance reimbursement attaches.

Licence types and costs. Four licence types — Manufacturer, Service Center Operator, Facilitator, Laboratory. Facilitator licensure requires an OPS-approved training programme (typically 120-hour curriculum at $7,000–$15,000 tuition), $150 application fee, and $2,000 annual licence fee; service-centre and manufacturer licences carry annual fees in the $10,000 range. Residency requirements expired 1 January 2025, enabling out-of-state capital.³¹

Q1 2025 metrics (Psychedelic Alpha tracker, drawing on OPS data):³² 1,509 distinct clients served in the quarter; 25 of 34 licensed Service Centers operational (nine closures since early 2024); 377 active Facilitators; 6 of 1,509 client sessions had adverse events requiring external intervention. Cumulative ~16,000 clients served programme-to-date; ~$1.7M OPS revenue. Average per-session client cost $1,000–$3,500 with no insurance coverage is the principal access barrier and a likely contributor to closures. The safety record (≈0.4% adverse events requiring intervention) is consistent with supervised-session models and with peer-reviewed Oregon safety reports.

After eighteen months of operation, the Oregon model is neither a runaway success nor a collapse: it is a small-but-real adult-use system with measurable client volume, a professionalising workforce, an evidence base for low serious-AE rates under trained supervision, and unresolved economic-sustainability questions (Ch. X).

11.4 Colorado Proposition 122 (Natural Medicine Health Act)

Colorado Proposition 122 passed in November 2022 with 53.6% in favour. Implementing legislation, SB23-290 (signed by Governor Polis on 23 May 2023), established the Natural Medicine Division within the Colorado Department of Revenue and the Natural Medicine Advisory Board. The framework is broader than Oregon’s in two respects: (i) it includes personal-use decriminalisation alongside the regulated healing-centre model, and (ii) it covers four substances (psilocybin, psilocyn, DMT, ibogaine, mescaline excluding peyote), although only psilocybin is permitted in the initial implementation phase, with the other three to be evaluated for inclusion starting 1 June 2026 on Advisory Board recommendation.³³³⁴

Final rules — for facilitator licensing, healing-centre operations, cultivation, manufacturing and testing — were finalised in a sequence between June and August 2025, with the first natural-medicine healing centres expected to commence operation in late 2025 and early 2026. Colorado law preserves a defence against criminal charges for personal use, cultivation and gifting (without remuneration) by adults aged 21 and over — a meaningful divergence from Oregon’s services-only model.

In May 2026, Governor Polis signed SB26-31 (one of a small set of “carve-out” bills clarifying interactions between the Natural Medicine Health Act and adjacent regulatory schemes, including criminal-justice and child-welfare statutes). The bill explicitly preserved the voter-approved Proposition 122 framework intact while clarifying boundary cases.³⁵

11.5 Other U.S.: city decriminalisation and the 2024 ballot-box correction

City-level decriminalisation spread rapidly 2019–2022 via council resolutions or ballot initiatives deprioritising enforcement of entheogenic plants and fungi; none has the effect of legalisation (possession remains a state and federal crime). Key milestones: Denver Initiated Ordinance 301, 7 May 2019 (50.6%, first U.S. jurisdiction);³⁶ Oakland Resolution 87731, 4 June 2019;³⁷ Santa Cruz, 28 January 2020;³⁸ Washington, D.C. Initiative 81, November 2020 (76%, effective 15 March 2021);³⁹ Somerville/Cambridge/Northampton (MA) 2021; Seattle, Arcata, and Detroit (61% ballot) 2021; Hazel Park, Easthampton, Port Townsend 2022. By 2026 roughly two dozen U.S. municipalities have adopted some variant. A growing number of states have enacted personal-use decriminalisation without services frameworks (California SB 58, October 2023; Utah HB 167 pilot; New Mexico HB 12, 2025).

State-ballot retreat. The most consequential corrective signal came in Massachusetts in November 2024, when Question 4 — an Oregon-style regulated psilocybin framework — was defeated approximately 57–43%.⁴⁰ The defeat was widely interpreted as evidence of voter cost-and-implementation fatigue following Oregon and Colorado, the proximity of the Lykos AdCom and CRL earlier in 2024, and well-funded opposition. No analogous statewide ballot has been certified for 2026; the post-Massachusetts pattern is a return to legislative-route reform.

11.6 Australia: TGA Schedule 8 (1 July 2023 onward)

Australia’s Therapeutic Goods Administration announced on 3 February 2023 a Poisons Standard reclassification of psilocybin (psilocybine) and MDMA from Schedule 9 (Prohibited Substances) to Schedule 8 (Controlled Drugs) for treatment-resistant depression (psilocybin) and PTSD (MDMA), effective 1 July 2023.⁴¹⁴² Outside those indications and the Authorised Prescriber (AP) framework, both remain Schedule 9. The decision made Australia the first jurisdiction to permit prescription outside a clinical trial. The AP scheme requires TGA-approved psychiatrist sponsorship with HREC endorsement, college-level psychiatry endorsement, and protocol compliance.

Patient numbers (September 2025). Psychedelic Alpha’s consolidated assessment: ~134 patients under the AP scheme — 87 MDMA-AT (PTSD), 47 psilocybin (TRD); ~13 active authorised prescribers across five states; no reported serious adverse events.⁴³

A regulatory distinction the panel should note. TGA Schedule 8 reclassification with Authorised Prescriber scheme is a scheduling action permitting individual prescriber sponsorship under HREC oversight — it is not the equivalent of FDA marketing authorisation of a labelled indication with standard-of-care prescriber discretion. Comparable FDA action is the Expanded Access (compassionate use) framework, not NDA approval. The AP scheme requires per-prescriber HREC approval, college-of-psychiatry endorsement, and protocol compliance; it operates as a closely-monitored pilot under sponsored individual-prescriber authority, not a population-scale deployment. TGA registration through the Australian Register of Therapeutic Goods (ARTG) standard — the closer parallel to FDA NDA approval — has not occurred for psilocybin or MDMA; both remain unregistered medicines in Australia. The ~134-patient cumulative cohort across 2.5 years is best read as a pilot-scale access mechanism with measurable safety record, not as a precedent that materially changes the worldwide marketing-authorisation landscape.

Cost and access. Out-of-pocket cost is the dominant barrier. Reported course costs: AUD $15,000–$35,000 (MDMA-AT, eight sessions plus three dosing days); AUD $10,000–$25,000 (psilocybin TRD). Medibank committed AUD $10 million in June 2025 to a pilot covering eligible policyholders, beginning with MDMA-AT and expanding to psilocybin.⁴⁴ The Department of Veterans’ Affairs subsequently committed to fund psychedelic-assisted therapy for eligible veterans — a first in any jurisdiction. The structural problem (Nutt, Br. J. Pharmacol. 2024) is the gap between regulatory permission and clinical scale-up: 134 patients across two years is pilot-scale, not population-scale, deployment.

11.7 EU, UK, Canada

Czech Republic. A psilocybin amendment bill passed the lower house of the Czech Parliament on 6 June 2025, was approved by the Senate, and was signed into law shortly thereafter; the regime permits medical use of synthetic psilocybin for treatment-resistant conditions (TRD, PTSD, substance-use disorders) administered by certified psychiatrists with psychedelic-therapy training in clinical settings with assisted psychotherapy, from 2026.⁴⁵

Germany. On 11 July 2025, the Federal Institute for Drugs and Medical Devices (BfArM) approved a Compassionate Use Programme for psilocybin in treatment-resistant depression — the first compassionate-access programme for a classical psychedelic in any EU member state. Two clinical sites (the Central Institute of Mental Health, Mannheim, and the OVID Clinic Berlin) are authorised to deliver the programme; demand is reported to exceed capacity by a wide margin.⁴⁶

Netherlands. The EU-funded PsyPal study commenced in early 2024, treating patients with end-of-life-adjacent diagnoses (COPD at UMCG Groningen; advanced parkinsonian disease at Champalimaud, Lisbon; multiple sclerosis at NIMH, Prague; ALS at the University of Copenhagen and Bispebjerg Hospital) under a clinical research authorisation framework.⁴⁷ Personal-use possession of psilocybin truffles for adult use remains effectively tolerated under longstanding Dutch practice, distinct from medical-access reform.

United Kingdom. No marketing authorisation has been granted by the MHRA for any psychedelic-assisted therapy. The MHRA continues to evaluate clinical trials of Schedule 1 substances under standard regulatory procedures. The most significant 2025 development is policy rather than statute: on 16 July 2025, the U.K. Government published its formal response to the Advisory Council on the Misuse of Drugs recommendation on Schedule 1 research, accepting an approach under which a domestic controlled-drugs licence will not be required for university, university college and hospital sites where MHRA, HRA or REC approval has already been obtained for a Schedule 1 study.⁴⁸ The change is implemented as a pilot rather than a full statutory reschedule; import/export and pharmaceutical manufacturing continue to require controlled-drug licensing. The effect, if the pilot is durable, is to remove a parallel-regulatory bottleneck that has historically inflated the cost and time of U.K. psychedelic research.

Canada. Health Canada has operated a Section 56 framework for individual exemptions since the 2020s. The two most consequential 2025 changes are: (i) a subsection 56(1) class exemption for participants enrolled in authorised clinical trials involving at-home administration of MDMA or psilocybin, effective 20 September 2025;⁴⁹ and (ii) the Special Access Program (SAP) for individual patient access to psilocybin or MDMA outside clinical-trial settings, which has been used cumulatively for approximately 301 approvals through mid-2025 — although PsyCan reporting in September 2025 noted that SAP approvals have fallen sharply year-on-year, with longer decision timelines and increased denial rates.⁵⁰ Additional regulatory changes are pending in late 2026.

11.8 Pharma economics: capital, valuations, consolidation

The psychedelic-biotech sector experienced a pronounced boom-and-correction cycle. Publicly reported financing was approximately $1.9 billion in calendar year 2021 (peak); cumulative 2022–2024 was ~$1.5 billion in aggregate. 2023 financing was ~49% lower than 2022 and >80% below 2021. A short-lived H1 2024 recovery (Compass and Cybin secondary offerings) gave way to a Q3 2024 contraction of >90% from the Q1 high, in part following the Lykos episode.⁵¹⁵² Aggregate listed-equity value against the Psychedelic Alpha index fell ~75% from the November 2021 high through end-2024.

As of the freeze date (13 May 2026), approximate market capitalisations of the most-watched listed companies (rounded, point-in-time):

The most significant consolidation of 2025 was the atai Life Sciences–Beckley Psytech merger. Announced June 2025 contingent on positive BPL-003 Phase 2b data, it closed 5 November 2025 at an implied Beckley valuation of ~$370M (BioWorld; alternative calculations ~$390M) with a $150M concurrent fundraise. Beckley shareholders received ~105M atai shares (≈31% of the combined entity, fully diluted). AtaiBeckley reports cash runway into 2029 with BPL-003 Phase 3 initiation in Q2 2026.⁵³

The remaining late-stage independent assets — COMP360, MM120, CYB003, GH001, luvesilocin/RE104 — are unlikely to all clear Phase 3 and regulatory review on independent runways under current capital-market conditions; further consolidation in 2026–2027 is the modal industry-analyst prediction. In regulatory terms, the field has split into a small group of cash-runwayed late-stage assets pursuing FDA approval on conventional NDA timelines and a markedly less well-capitalised constellation of training organisations, retreat operators, and clinic networks operating under state-level regimes. The two ecosystems share investors, advocates and chemistry, but answer to different regulatory authorities on different timelines — and the 2024 correction has, if anything, sharpened the divergence.

The aggregate valuation pool tabulated above — on the order of $2.1–3.7 billion across the five most-watched listed psychedelic-pharma companies as of the freeze date — is built on intellectual-property portfolios for molecules with documented Indigenous antecedents (psilocybin: Mazatec; mescaline: Wixárika and Native American Church; 5-MeO-DMT: Amazonian yopo tradition and Brazilian ayahuasca communities; LSD: derivative of ergoline alkaloids first known to European but plausibly also Aztec ritualists through ololiuqui/morning glory). None of the active patent portfolios at the five listed companies is, to public knowledge, encumbered by a reciprocal licence obligation tied to a specific source community. The cost of building a credible reciprocity infrastructure — equity allocations, royalty obligations to community-led benefit-sharing trusts, the IRIA framework developed by Chacruna and elaborated in the Celidwen 2022 Lancet Regional Health – Americas eight-principle consensus — is not currently priced into any company’s projected operating costs or valuation. Ch X §10.7 develops the substantive case; Ch XIII §13.6 returns to the question as a 5–10-year structural priority for the field.

11.8a Patent life, NCE exclusivity, and the generic-pathway timeline

The valuation pool is conditional on exclusivity assumptions that bear scrutiny. Psilocybin is a naturally occurring small molecule with extensive prior art — Hofmann’s 1958 isolation and structural characterisation,⁵⁴ continuous Mazatec ceremonial use predating the Western literature by centuries, and a half-century of medicinal-chemistry literature — making composition-of-matter patenting of the molecule itself impossible under §102 novelty grounds. What is patented at the major commercial-stage developers is therefore not the molecule but, in roughly increasing order of defensibility under invalidity challenge:

• Synthesis-method patents (Kargbo et al. 2020 ACS Omega second-generation route used by Compass for COMP360 manufacturing; analogous process IP at Filament Health for botanical sourcing, Cybin for deuterated-analogue synthesis). Synthesis-method patents are relatively narrow and routinely worked around by alternative routes.
• Polymorph/crystal-form patents. Compass’s COMP360 patent portfolio is anchored on Polymorph A — a specific crystalline form of psilocybin characterised by X-ray powder diffraction signatures — with the foundational US Patent 11,851,451 covering both the polymorph and the synthesis to produce it. The Polymorph A patent has been challenged at the Patent Trial and Appeal Board (PTAB) by Freedom to Operate and was upheld in 2022–2023, but the underlying invalidity question (whether Polymorph A is a non-obvious crystalline form given prior psilocybin synthesis literature) remains a live issue that paragraph-IV ANDA challengers may revisit.⁵⁵
• Formulation patents. Tablet formulations specifying excipient combinations (microcrystalline cellulose as the principal binder for COMP360), dosage form, and stability profile. These are routinely the strongest small-molecule patents because reformulation around them is operationally expensive.
• Method-of-use patents. Compass holds US Patent 10,519,175 covering the use of its psilocybin formulation in a structured psilocybin-with-psychological-support protocol for TRD; analogous method-of-use claims for related indications are pending. Method-of-use patents are challengeable under §103 obviousness when prior-art use (Mazatec velada; pre-2010 open-label psilocybin trials) is documented, but the specific protocol claims (dose, timing, support structure) carry stronger novelty arguments.
• Analogue / prodrug composition-of-matter patents. Cybin’s CYB003 (deuterated psilocin) and Reunion’s luvesilocin (RE104, O-glutaryl psilocin prodrug) are novel chemical entities under §102 — different molecules from psilocin with their own composition-of-matter patents and independent NCE exclusivity claims. This is the principal patent-life-extension rationale for the deuterated and prodrug analogue programmes.

The Hatch-Waxman regulatory-exclusivity layer is independent of the patent layer. FDA approval of a “new active moiety” grants 5 years of New Chemical Entity (NCE) exclusivity under §505(c)(3)(E)(ii), during which FDA cannot accept a generic ANDA referencing the approved drug.⁵⁶ Whether psilocybin qualifies as a “new active moiety” is contested — the molecule’s prior characterisation in the literature (Hofmann 1958) and prior FDA awareness (DEA Schedule I listing 1971) may complicate the determination; the Compass NDA package will plausibly argue NCE status on the grounds that psilocybin has never previously been approved by FDA in any form. If granted, NCE exclusivity prevents ANDA filing for 5 years post-approval; thereafter, paragraph-IV ANDA filings can challenge the listed Orange Book patents, with the first-to-file generic receiving 180 days of generic-exclusivity if it prevails. The projected generic-entry timeline under this framework is 4–5 years post-approval at the earliest, with the practical timeline plausibly closer to 6–8 years depending on patent-challenge outcomes and ANDA review queues.

The Cybin and Reunion analogue strategies are partly motivated by extending the exclusivity horizon: deuterated psilocin and O-glutaryl psilocin would each plausibly qualify as new active moieties with their own 5-year NCE exclusivity (effectively resetting the generic clock), and method-of-use and formulation patents on those analogues would layer on top. The Beckley/atai BPL-003 (mebufotenin benzoate) and GH Research GH001 (mebufotenin free base) programmes similarly anchor on novel-salt-form or novel-delivery-device claims; the underlying molecule is well-characterised but the formulations are patentable. The aggregate valuation pool tabulated in §11.8 embeds an implicit assumption that the patent + NCE protection holds for 8–10 years post-approval — which is defensible for Compass (Polymorph A + method-of-use + NCE) but not certain.

11.8b EMA’s distinct posture and the EU pathway

The European Medicines Agency has not granted marketing authorisation for any psychedelic and has not, as of the freeze date, issued a public Scientific Advice characterising the evidentiary expectations for a psilocybin Marketing Authorisation Application (MAA). EMA hosted a multi-stakeholder workshop on psychedelics in 2024 (“Towards an EU regulatory framework”), the principal public-record event characterising EMA’s current thinking.⁵⁷ Compass has run a single EU/UK Phase 3 trial (in the UK, Czech Republic, Denmark, Germany, Portugal, Spain, and the Netherlands, launched 2023) that would form part of a centralised MAA package, but the public record does not include an EMA Scientific Advice opinion specific to the COMP360 evidentiary plan.

The EU regulatory architecture differs from FDA in three load-bearing ways:

1. Centralised vs national authorisation. Centralised authorisation through EMA’s Committee for Medicinal Products for Human Use (CHMP) is the standard pathway for novel psychiatric agents and is required for orphan-designated products; once granted, the marketing authorisation is valid across all EU member states. Compass’s commercial strategy for EU access plausibly targets centralised authorisation, but this has not been publicly confirmed. National compassionate-use programmes (Germany BfArM 2025, Czech 2025 medical-access bill — §11.7) operate under Article 5(1) of Directive 2001/83/EC, which permits Member State patient-access schemes outside the centralised authorisation procedure for unauthorised medicines. These are not equivalent to centralised authorisation; they are member-state-level access mechanisms for unapproved medicines and do not generalise across the EU.
2. Paediatric Investigation Plan (PIP) requirement. EMA’s PIP requirement is more onerous than FDA’s PREA: a PIP is required for any new MAA unless an EMA waiver is granted, with the PIP submitted at end of Phase 1 (earlier than FDA’s iPSP). For psilocybin, EMA paediatric requirements are plausibly stricter than FDA’s, and the centralised authorisation timeline will be paced by PIP-completion or PIP-waiver timing.
3. Scientific Advice procedure. EMA’s Scientific Advice through the CHMP Scientific Advice Working Party (SAWP) is the recommended pre-MAA engagement; Compass has plausibly used this procedure but no public Scientific Advice opinion on COMP360 has been disclosed. The 2024 EMA workshop is the closest public-record document characterising EMA’s general posture.

The MHRA-UK post-Brexit position is a separate track from EMA; the July 2025 controlled-drugs licence waiver for academic Schedule 1 research (§11.7) is a research-friction reduction, not a marketing pathway change. The Czech Republic’s 2026 implementation, the German compassionate-use programme, and the Dutch PsyPal trial are not steps toward an EMA centralised authorisation; they are independent national-level access mechanisms.

The panel-relevant takeaway is that the report’s “fragmented EU progress” framing in §11.7 should be read as describing patient-access mechanisms under national-level discretion, not as EU-wide regulatory progress. EMA centralised authorisation has not been pursued or granted for any psychedelic, and the EU regulatory posture for psilocybin marketing approval remains materially distinct from FDA’s — both because EMA has not publicly engaged the evidentiary expectations and because the EU’s structurally-different national-vs-centralised dual track creates parallel patient-access pathways that do not aggregate to an EU-wide regulatory verdict.

References

← Ch. X · Overview · Ch. XII →